Clinical Trials
76 trialsChemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer
NRG Oncology
HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma
University of Pittsburgh
Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
National Cancer Institute (NCI)
Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine
OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
PEACH
Royal Marsden NHS Foundation Trust
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
Eastern Cooperative Oncology Group
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer
M.D. Anderson Cancer Center
Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer
University of Michigan Rogel Cancer Center
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
KEYNOTE-412
Merck Sharp & Dohme LLC
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
Radiation Therapy Oncology Group
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer
National Cancer Institute (NCI)
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Incyte Corporation
ELEVATE HNSCC
Gilead Sciences
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
EMD Serono
ECHO-07
GERCOR - Multidisciplinary Oncology Cooperative Group
DEPEND
University of Chicago
OPTIMA-II
University of Chicago
Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer
City of Hope Medical Center
NEOPBOSCC
Hospital of Stomatology, Wuhan University
De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study
UNC Lineberger Comprehensive Cancer Center
APA
Washington University School of Medicine
De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca
UNC Lineberger Comprehensive Cancer Center
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
Dana-Farber Cancer Institute
OPTIMA
University of Chicago
Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer
University of Pittsburgh
Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
M.D. Anderson Cancer Center
The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL)
Icahn School of Medicine at Mount Sinai
P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC
UNC Lineberger Comprehensive Cancer Center
Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer
The University of Texas Health Science Center at San Antonio
Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer
Canadian Cancer Trials Group
Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer
Radiation Therapy Oncology Group
Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck
Eastern Cooperative Oncology Group
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
Eastern Cooperative Oncology Group
Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer
National Cancer Institute (NCI)
Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
PRV111
Privo Technologies
IT-MATTERS
CEL-SCI Corporation
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Radiation Therapy Oncology Group
CHANGE2
Merck KGaA, Darmstadt, Germany
Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer
Ohio State University Comprehensive Cancer Center
KESTREL
AstraZeneca
A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer
Galera Therapeutics, Inc.
Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer
Bristol-Myers Squibb
Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer
Rutgers, The State University of New Jersey
Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer
Washington University School of Medicine